Clinical trial NCT00714948: Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Official title: Phase II Study of Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Bladder Cancer
URINARY BLADDER
Keywords: Bladder
Urinary
SORAFENIB
CISPLATIN
GEMCITABINE
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
Collaborators: name: Bayer
First posted: 2008-07-14
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Standard chemotherapy drugs generally work by killing rapidly dividing cells in your body. Cancers cells are some of the most rapidly dividing cells and that is why chemotherapy can be effective in some patients. Gemcitabine and Cisplatin are an effective and standard drug combination used to treat locally advanced and metastatic urothelial cancer. However, these drugs do not shrink tumors in all patients and when they do, it is generally for a limited amount of time. This has led scientists to look for different ways to treat cancer.

New drugs have been developed to treat cancer that work differently than standard chemotherapy drugs. These drugs attempt to decrease the blood supply to tumors. By doing so, this may limit the tumor's source of oxygen and nutrients and prevent the tumor from growing. Sorafenib is an example of a drug that works in this way.

In some patients with advanced kidney cancer, sorafenib alone has been shown to slow the progression of their disease. The purpose of this study is to find out what effects, good and/or bad, the combination of gemcitabine, cisplatin, and sorafenib has on you and your cancer.


Eligibility criteria: Inclusion Criteria:

* Patients must have measurable or evaluable urothelial cancer.

  * Measurable disease includes unresectable or metastatic urothelial tract tumors that are unidimensionally measurable by xray,CT/MRI scan or physical examination.
  * Evaluable disease is restricted to patients with unresectable primary bladder tumors which can be evaluated for response by cystoscopy.
* Pathologic confirmation by the Department of Pathology at MSKCC.
* Karnofsky Performance Status (KPS) ≥60%.
* Adequate marrow function defined as granulocytes ≥ 1500 cells/mm 3 , platelets ≥ 100,000 cells/mm 3 , and hemoglobin ≥ 8.0 g/dl.
* Serum creatinine \< 2.0 mg/dl
* 24-hour urine sample demonstrating creatinine clearance ≥ 60 ml/min/1.73m2 or calculated creatinine clearance ≥ 60 ml/min/1.73m 2 using the formula: Jeliffe Equation: estimated creatinine clearance = 98 x (0.8 \[age(yrs) 20\]/Serum Creatinine (mg/dL) x (0.9 if Female))
* Adequate hepatic function defined as:

  * Total Bilirubin \< or = to 1.5 x ULN
  * AST and ALT \< or = to 3.0 x ULN (\< or = to 5.0 x ULN is acceptable if liver has tumor involvement)
* Normal coagulation profile including PT/INR and PTT, unless patient is receiving anticoagulation therapy with agents such as warfarin or heparin.
* Age ≥ 18 years
* Informed consent
* Women of childbearing potential must have a negative pregnancy test.
* Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.
* Patients are encouraged to continue barrier method contraception for two years or longer after treatment.

Exclusion Criteria:

* Prior treatment with systemic chemotherapy (prior intravesical therapy is permitted).
* Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study.
* Blood Pressure of \> 150/100 mm Hg.
* Irradiation within 4 weeks of start of protocol.
* Evidence of another active cancer, except for nonmelanoma skin carcinoma, insitu carcinoma of the cervix curatively treated, and adenocarcinoma of the prostate that has been surgically treated with a post-treatment PSA that is nondetectable.
* Significant cardiovascular disease including congestive heart failure (New York Heart Association Class II or higher) or active angina pectoris.
* History of a myocardial infarction within 6 months.
* History of a stroke or transient ischemic attack within 6 months.
* Clinically significant peripheral vascular disease.
* Evidence of bleeding diathesis or coagulopathy.
* Presence of central nervous system or brain metastases.
* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0.
* Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 0.
* History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 6 months prior to Day 0.
* Serious nonhealing wound, ulcer, or bone fracture.
* History of persistent gross hematuria.
* Uncontrolled infection.
* Hypersensitivity to sorafenib, or any component of the formulation.
* Pregnant (positive pregnancy test) or lactating.
* Inability to comply with the study and/or followup procedures.

Primary outcomes:
measure: To Determine the Progression Free Survival Rate at One Year Untreated Patients With Advanced/Metastatic Urothelial Carcinoma Treated With the Combination of Sorafenib, Gemcitabine, and Cisplatin.
timeFrame: conclusion of the study
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Matthew Milowsky, MD
role: PRINCIPAL_INVESTIGATOR
References: